drugset / Trial / NCT03126760

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

NCT03126760

Phase 4 Terminated 35 enrolled Mallinckrodt
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will enroll about 66 participants who experienced a relapse of RRMS that steroids did not help. The doctor will put participants into a treatment group. Each person has an equal chance of being in either one of two groups (like flipping a coin). One group will receive a shot of study medicine (called Acthar Gel) under their skin every day for 14 days. The other group will receive a shot every day for 14 days, too, but there is no medicine in it (called placebo).

Timeline

Start
2017-05-22
Primary completion
2020-07-14
Completion
2020-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Acthar Peptide 1 ml Subcutaneous
Subject Acthar Peptide 80 iu Subcutaneous